Idiopathic pulmonary hemosiderosis (IPH) is a rare condition where children experience repeated internal bleeding in the lungs, often with no clear cause. While most children respond well to standard immunosuppressive treatments (medications that calm down an overactive immune system), some become resistant to these therapies or dependent on high doses of steroids without achieving lasting improvement.
A recent case study examined two children with steroid-resistant or steroid-dependent IPH—meaning their bodies no longer responded adequately to high-dose corticosteroids despite aggressive treatment. Both children had severe, recurrent lung bleeding that left doctors and parents searching for alternatives.
Rituximab stopped the bleeding and reduced steroid dependence
After receiving rituximab, a type of targeted immunotherapy already used safely for other childhood immune conditions, both children experienced rapid and sustained control of their lung bleeding. Crucially, they were able to gradually reduce and eventually taper their corticosteroid doses—a significant breakthrough since long-term steroid use in children carries real risks: weakened bones, growth delays, and increased susceptibility to infection.
Neither child experienced serious adverse effects from rituximab during the six-month follow-up period, and neither experienced a relapse of lung bleeding.
Important limitations: this is a small study, not yet proof for all children
This research is based on only two children, not a large-scale clinical trial. While the results are promising and encouraging for families facing steroid-resistant IPH, the evidence remains limited. Treatment decisions must always be individualised, as every child's condition is different. Parents whose child has IPH and isn't responding well to conventional treatments should discuss whether rituximab might be suitable with their paediatric pulmonologist or immunologist.
Next steps if your child has steroid-resistant IPH
- Ask your child's doctor about rituximab if standard steroids and immunosuppressants have not achieved sustained control after a reasonable trial period.
- Request a referral to a paediatric immunologist or pulmonologist with experience managing severe IPH cases for specialist input.
- Discuss the specific risks and benefits of rituximab for your child's situation, including infection monitoring plans during treatment.